K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease
Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model
Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches
Objective: To validate effect of Indolocarbazole derivatives on Cyclin dependent kinase for treating Parkinson's (Preliminary work in context of CDK5 assay and Simulations have been…A Theranostic Approach to Intervene the Link Between Parkinson’s Disease (PD) and LRRK – 2 Mutation
Objective: The current research work encircles the main perspective of screening patients for PD with LRRK-2 mutations in patients pertaining to regions in and around…Expression of late cell cycle markers in Parkinson Disease and Lewy Body Dementia
Objective: The objective of this study is to determine the expression of late cell cycle markers in Parkinson Disease (PD) and Lewy Body Dementia (LBD) Background:…Long-Term Dopamine Transporter Imaging and Clinical Effects of the Mixed-Lineage Kinase Inhibitor CEP-1347 in the PRECEPT Parkinson Trial
Objective: To assess the imaging and clinical effects of CEP-1347 after treatment discontinuation in the Parkinson Research Examination of CEP-1347 Trial (PRECEPT), a multi-center randomized…Phosphorylation by GSK-3β enhances binding of metal ion induced tau oligomers to neutral lipid surfaces
Objective: To dissect the complex interplay of tau hyperphosphorylation, metal ion induced oligomer formation and membrane interactions applying single particle fluorescence techniques. Background: Fibrillar deposits…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.